

Newfoundland and Labrador Pharmacy Board



Provincial Drug Schedules

August 2021

TABLE OF CONTENTS

INTRODUCTION	3
SCHEDULE I	4
SCHEDULE II	6
SCHEDULE III	11
UNSCHEDULED DRUG PRODUCTS	16
APPENDIX A - PROVINCIAL REGULATIONS	19
APPENDIX B - SCHEDULING CRITERIA	20
APPENDIX C - VACCINES QUICK REFERENCE	22

INTRODUCTION

General

In November 2014, changes were made to the Newfoundland and Labrador Drug Scheduling process in accordance with the new Pharmacy Regulations, 2014 (see Appendix A). As such, changes to the provincial drug schedules are now reviewed and approved by the Newfoundland and Labrador Pharmacy Board rather than the Minister of Health and Community Services.

This approval process will still be based on the recommendations of the National Drug Scheduling Advisory Committee, as described below. Once a recommended change is received by the Newfoundland and Labrador Pharmacy Board, it is added to the agenda for the next Board meeting for review and approval. **A recommended change is NOT effective until it has received Board approval.**

National Drug Scheduling Advisory Committee

In May 1995, the National Association of Pharmacy Regulatory Authorities (NAPRA) approved a national scheduling model and, to ensure ongoing review and maintenance of the drugs listed in the model schedules, established the National Drug Scheduling Advisory Committee (NDSAC) in August 1995. NDSAC includes experts from across Canada as well as other relevant representatives and is mandated to advise the provincial regulatory authorities on matters relating to the placement of drugs within the national scheduling model and to continually evaluate and maintain the drug scheduling factors within the model (see Appendix B).

NDSAC meets several times throughout the year to review and analyse submissions from sponsors requesting scheduling additions or revisions, generally in response to:

- A federal government proposal to deregulate a federal prescription status drug;
- A new drug approved for sale in Canada on a non-prescription basis; or
- A request from a manufacturer, the public or other stakeholder to reassess or review the current recommended schedule status of a drug.

For a full overview of NDSAC's policies and procedures, please visit napra.ca/drug-scheduling-canada-general-overview.

SCHEDULE I – PRESCRIPTION SALE ONLY

Schedule I drugs require a prescription for sale and are provided to the public by the pharmacist following the diagnosis and professional intervention of a practitioner. They are in addition to, but subject to the same conditions as, the drugs listed in the Prescription Drug List established in accordance with section 29.1 of the Food and Drugs Act and its accompanying Regulations (Canada).

Some drugs on this schedule may appear to be non-prescription drugs since there is no “Pr” symbol directly on the product. Pharmacists must be aware of these products to prevent possible sale without a prescription.

The following table provides a current list of Schedule I drugs. **Recent changes are indicated with BOLD UNDERLINE.** Examples of the Brand Names of products containing these drugs are also provided. Please note that the list of Brand Names is not necessarily inclusive and are provided for reference only.

Chemical name as it appears in the Schedule	Examples of common Brand Names
allergy serums and extracts	
alpha 1-proteinase inhibitor (human)	
alverine and its salts for parenteral use	
amino acid solutions for parenteral use	
aminopromazine [proquamezine] and its salts	
bacillus Calmette-Guerin vaccine	
bacitracin and its salts and derivatives for parenteral use	
calcium chloride in injectable form for parenteral nutrition	
calcium gluconate in injectable form for parenteral nutrition	
cholera vaccine except oral, inactivated, when used for prophylaxis against Traveler’s Diarrhea due to enterotoxigenic escherichia coli [ETEC]	
chromium chloride (chromic chloride) in injectable form for parenteral nutrition	
copper chloride (cupric chloride) in injectable form for parenteral nutrition	
copper sulphate in injectable form for parenteral nutrition	
cytomegalovirus immune globulins	
dextrose injection in concentrate solutions for parenteral nutrition	
encephalitis vaccine (Japanese)	
ephedrine and its salts in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion	
epinephrine and its salts (other than in pre-filled syringes intended for emergency administration by injection in the event or anaphylactic reactions to allergens)	
erythryl tetranitrate	
esomeprazole or its salts, except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole	
ethylpapaverine and its salts	
flumazenil	
hepatitis A vaccine	
hepatitis B adult vaccine	
hepatitis B immune globulin	
herpes zoster (shingles) vaccine (live)	
homatropine and its salts for ophthalmic or parenteral use or in preparations for oral use containing more than 2 mg per dosage unit	
hydrocortisone or hydrocortisone acetate, when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing more than 30g	
hydrocortisone or hydrocortisone acetate, when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in children under 2 years of age	
immune globulin products	
isopropamide and its salts	
isosorbide and its salts	• Imdur
levallorphan and its salts	

Chemical name as it appears in the Schedule	Examples of common Brand Names
lipid solutions in injectable form for parenteral nutrition	
Lyme Disease vaccine	
magnesium sulphate in injectable form for parenteral nutrition	
manganese and its salts in injectable form for parenteral nutrition	
metaraminol bitartrate	
mupirocin	<ul style="list-style-type: none"> • Bactroban
naproxen and its salts, except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base	<ul style="list-style-type: none"> • Anaprox • Naprosyn
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]	
nicotiny-tartrate	
nikethamide	
nitroglycerin (except for sublingual immediate release dosage forms)	<ul style="list-style-type: none"> • Minitran • Nitro-Dur • Transderm-Nitro • Trinipatch
omeprazole or its salts (except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole)	
orphenadrine hydrochloride	
papaveretrine and its salts	
papaverine and its salts	
pentaerythritol tetranitrate	
potassium salts in preparations for injection	
proquamezine [aminopromazine] and its salts for internal use	
quinidine salts	
rabies immune globulin	
rabies vaccine	
rho D immune globulin	
selenium in injectable form for parenteral nutrition	
sodium acetate in injectable form for parenteral nutrition	
sodium chloride in injectable form for parenteral nutrition	
sodium iodine in injectable form for parenteral nutrition	
sodium phosphate in injectable form for parenteral nutrition	
streptokinase/streptodormase	
succinylcholine and its salts	
tetanus immune globulin	
typhoid vaccines / salmonella typhi vaccines	
vaccines (except those part of a routine immunization program in most/all provinces & territories: cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea and due to enterotoxigenic escherichia coli (ETEC); diphtheria toxoid, haemophilus influenzae type b, hepatitis B pediatric, influenza, measles, mumps, pertussis, pneumococcus, poliomyelitis, rubella, tetanus toxoid; and those requiring special enhanced public access due to disease outbreaks: meningococcus)	
varicella vaccine (chicken pox)	
varicella zoster immune globulin	
vitamin K (except Vitamin K1 and Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less)	
vitamins in injectable form for parenteral nutrition	
yellow fever vaccine	
zinc chloride in injectable form for parenteral nutrition	
zinc sulphate in injectable form for parenteral nutrition	

SCHEDULE II – SALE ONLY FROM A NO PUBLIC ACCESS AREA OF A DISPENSARY

Schedule II drugs, while less strictly regulated, do require professional intervention from the pharmacist at the point of sale and possibly referral to a practitioner. While a prescription is not required, the drugs are available only from the pharmacist and must be retained within an area of the pharmacy where there is no public access and no opportunity for patient self-selection.

Pharmacists have a professional responsibility to ensure patients are knowledgeable about the appropriate selection of a Schedule II drug depending on symptoms, compatibility with other drugs being used, efficacy, possible adverse drug reactions, expected outcomes and what to do if outcomes are not achieved.

The following table provides a current list of Schedule II drugs. **Recent changes are indicated with BOLD UNDERLINE.** Examples of the Brand Names of products containing these drugs are also provided. Please note that the list of Brand Names is not necessarily inclusive and are provided for reference only.

Chemical name as it appears in the Schedule	Examples of common Brand Names
acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen	
acetarsol	
acetylcysteine	
acetylsalicylic acid (ASA) and its salts (in oral preparations containing 80 mg or less per dosage unit and intended for pediatric use OR rectal preparations containing 150 mg or less per dosage unit, in package sizes containing no more than 1.92 g of acetylsalicylic acid)	<ul style="list-style-type: none"> Asaphen Chewable 80mg Asatab 80mg Chewable
adiphen and its salts for parenteral use	
allethrins	
amylocaine and its salts (for ophthalmic or parenteral use)	
anisotropine and its salts	
anthralin	
antihemophilic factor, human	
antipyrine (except otic preparations)	
apomorphine and its salts	
arginine and its salts	
artemisia, its preparations, extracts and compounds (except in trace amounts in homeopathic preparations)	
belladonna alkaloids and their salts and derivatives (except in preparations for topical use or in trace amounts in homeopathic preparations)	
benoxinate hydrochloride (oxybuprocaine) for ophthalmic or parenteral use	
bentiromide	
benzalkonium and its salts (liquid preparations in concentrations greater than 2%)	
benzethonium chloride (liquid preparations in concentrations greater than 1%)	
benzocaine and its salts (for ophthalmic or parenteral use)	
benzyl benzoate	
boric acid and its salts (in preparations for systemic or ophthalmic use in concentrations greater than 2%, except in contact lens solutions intended to be rinsed off prior to insertion in the eye.)	
buclizine	
bufexamac	
bupivacaine and its salts (for ophthalmic or parenteral use)	
butacaine and its salts (for ophthalmic or parenteral use)	
calcium disodium edentate	
camphor (in oleaginous vehicles and in liquid forms in concentrations greater than 11%)	
cantharides, their preparations and derivatives	
charcoal (activated) for use in poisoning treatment	
chloroprocaine and its salts (for ophthalmic or parenteral use)	
cholecystokinin	
cholera vaccine (oral, inactivated) when used for prophylaxis against Traveler's Diarrhea due to enterotoxigenic escherichia coli [ETEC]	<ul style="list-style-type: none"> Dukoral
choline bitartrate (for parenteral use)	

Chemical name as it appears in the Schedule	Examples of common Brand Names
chymopapain (for parenteral use)	
chymotrypsin (for ophthalmic and parenteral use)	
cinchocaine (dibucaine) and its salts (for ophthalmic or parenteral use)	
clidinium and its salts	
clobetasone butyrate (when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin)	<ul style="list-style-type: none"> • Specto EczemaCare Medicated Cream
coal tar (in concentrations greater than 10%)	<ul style="list-style-type: none"> • Odans Liquor Carbonis Detergens
codeine and its salts (in preparations exempted from the Regulations to the Controlled Drugs and Substances Act – i.e. not more than 8 mg or its equivalent of codeine phosphate per solid form or not more than 20 mg or its equivalent of codeine phosphate per 30 mL in a liquid preparation) (Please Note: These preparations should be stored in accordance with the Regulations to the Controlled Drugs and Substances Act)	
collagenase (as a debriding agent)	
crotamiton	<ul style="list-style-type: none"> • Eurax
cylandelate	
cyclazocine and its salts	
cyclomethacaine and its salts (for ophthalmic or parenteral use)	
cyclopentamine and its salts	
cyclopentolate and its salts (except in products for ophthalmic or parenteral use)	
cyproheptadine and its salts	
desoxyribonuclease [pancreatic dormase]	
dextrose (sclerosing agents)	
diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days - in concentrations greater than 1.16% and less than or equal to 2.32% - in package sizes containing greater than 2.6g of diclofenac diethylamine	<ul style="list-style-type: none"> • Voltaren Emulgel Extra Strength products (in package sizes greater than 112 gm)
dicyclomine and its salts (except for topical use and lozenges)	
dihydroquinidine and its salts (except phenylbarbiturate)	
diiodohydroxyquin (for topical use on the skin)	
dimenhydrinate and its salts (for parenteral use)	<ul style="list-style-type: none"> • Gravol IM injection
diperodon and its salts (except for topical use)	
diphenhydramine and its salts and preparations (for parenteral use)	
diphenhydramine and its salts and preparations (for topical use in concentrations of greater than 2%)	
diphtheria toxoid	
dyclonine (except for topical use on mucous membranes)	
ephedrine and its salts in single entity products (in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use for not more than 7 days, and indicated for nasal congestion)	
epinephrine and its salts (in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens.)	<ul style="list-style-type: none"> • Epipen / Epipen Jr.
esdepallethrin/piperonyl butoxide	
ethanolamine oleate	
ethoheptazine and its salts	
ethyl chloride (except in trace amounts)	
fibrin	
fibrinolysin	
fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 360 metered sprays	
gentian violet (for application to skin or mucous membranes)	
glucagon	
glycopyrrolate and its salts	
hemophilus influenzae type B vaccine	
heparin and its salts (except for topical use)	
hepatitis B pediatric vaccine	
herpes zoster (shingles) vaccine (non-live recombinant)	Shingrix
histamine and its salts (except for topical use)	

Chemical name as it appears in the Schedule	Examples of common Brand Names
homatropine and its salts (for oral use in concentrations of 2 mg or less per dosage unit)	
human insulin	
human papillomavirus vaccine	
hyaluronic acid and its salts (preparations in concentration of 5% or more)	
hyaluronidase	
hydroquinone (topical preparations)	
hydroxyephedrine and its salts	
hyoscine and its salts and derivatives (except for parenteral use)	<ul style="list-style-type: none"> • Buscopan tablets
hyoscyamine and its salts and derivatives (except for topical use)	
influenza vaccine	
insulin	
iodinated glycerol	
iodine and its salts and derivatives (except in topical preparations or in oral doses of 1 mg or less per day)	
iodochlorhydroxyquin (for topical use)	
ipecac & its extracts & derivatives (when used as an emetic)	
iron and its salts and derivatives (in preparations with more than 30mg elemental iron per unit or 5ml liquid) <p style="text-align: center;"><u>30mg elemental iron equals:</u> ferrous ascorbate 250mg ferrous fumarate 92mg ferrous gluconate 257mg ferrous sulphate 150mg</p>	<ul style="list-style-type: none"> • Feramax products • Neo-Fer / Neo-Fer Cf • Palafer capsules / suspension / Palafer CF
levargorphane and its salts	
levonordefrine	
levonorgestrel (when sold in concentrations of 0.75 mg per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.))	
lidocaine and its salts (for ophthalmic or parenteral use or topical use on mucous membranes except lozenges)	<ul style="list-style-type: none"> • Xylocaine Viscous
lindane	
loperamide and its salts in products marketed for pediatric use – under 12 years of age	
magnesium sulphate (for parenteral use)	
mannitol and its salts	
measles vaccine	
meningococcus vaccine	
mepivacaine and its salts (for ophthalmic or parenteral use)	
metathoheptazine and its salts	
methantheline	
methdilazine and its salts	
methenamine and its salts (except for topical use)	
metheptazine and its salts	
methocarbamol (for parenteral use)	
methyl salicylate (in liquid dosage forms in concentrations greater than 30%)	
methylene blue (for parenteral use)	
monobenzone	
monoethanolamine oleate	
mumps vaccine	
naloxone hydrochloride injection, when indicated for emergency use for opioid overdose naloxone hydrochloride nasal spray, when indicated for emergency use for opioid overdose (Please also see NLPB Guidelines on the Sale of Naloxone Injection in Community Pharmacies ¹)	

¹ Available on the Standards, Guidelines, Policies and Positions page of the NLPB website: <https://nlpb.ca/pharmacy-practice/standards-guidelines-policies/>

Chemical name as it appears in the Schedule	Examples of common Brand Names
naphazoline and its salts (in nasal preparations for pediatric use)	
niacin [nicotinic acid] (in extended release formulations)	
nitroglycerin (sublingual immediate release dosage forms)	<ul style="list-style-type: none"> Nitrolingual Pumpspray Nitrostat 0.3mg / 0.6mg tablets
norepinephrine and its salts [levarteronol, noradrenaline]	
omeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20mg, in package sizes of no more than 280mg of omeprazole	<ul style="list-style-type: none"> Heartburn Control (Apotex) Omep
oxymetazoline and its salts (in nasal preparations for pediatric use)	
oxyquinoline	
paroxypropione	
pentagastrin and its salts	
permethrin and its derivatives	<ul style="list-style-type: none"> Kwellada-P cream rinse / lotion Nix cream rinse / Nix dermal cream
pertussis vaccine	
phenol (preparations with concentrations greater than 20%)	
phenoxybenzamine and its salts	
phenylephrine and its salts and preparations (in nasal preparations in concentrations of 2.5% or less for pediatric use)	
physostigmine salicylate (for oral or topical use)	
piperazine and its salts	
pneumococcal polysaccharide vaccine	
pneumococcal 7-valent conjugate vaccine	
pneumococcal 13-valent conjugate vaccine	
poliomyelitis vaccine	
polyacrylamide	
potassium salts (in preparations containing greater than 5 mmol per dose)	
povidone-iodine (vaginal preparations, except in concentrations of 5 % or less)	
pramoxine and its salts (for ophthalmic or parenteral use)	
prilocaine and its salts (for ophthalmic or parenteral use)	
procaine and its salts (for ophthalmic or parenteral use)	
promethazine and its salts (except for topical use)	
propantheline and its salts	
proparacaine and its salts (for ophthalmic or parenteral use)	
propylhexidine	
protamine and its salts	
pseudoephedrine and its salts and preparations in single entity products	
pyrantel and its salts	<ul style="list-style-type: none"> Combantrin products
pyrethrins	
pyrethrins/piperonyl butoxide	<ul style="list-style-type: none"> R&C Shampoo with Conditioner
pyrivinium and its salts	
racemethionine	
rose bengal	
rotavirus vaccine	
rubella vaccine	
rue and its preparations and extracts	
salicylic acid and its salts (in topical preparations in concentrations greater than 40%)	
silver nitrate	
sincalide	
sodium acetate (for parenteral use)	
sodium biphosphate (for parenteral use)	
sodium chloride (single ingredient solutions for parenteral or ophthalmic use in concentrations greater than 0.9%) [Does not apply to contact lens products intended to be rinsed off prior to insertion in the eye.]	
sodium citrate (for parenteral use)	
sodium iodide (for sclerosing)	
sodium phosphate (for parenteral use)	

Chemical name as it appears in the Schedule	Examples of common Brand Names
sodium picosulphate for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5g and citric acid 12g)	<ul style="list-style-type: none"> • Pico-Salex • Purg-Odan
sodium tetradecyl sulphate	
stramonium, its preparations, extracts and compounds	
streptokinase (as a debriding agent)	
strontium and its salts (for parenteral use)	
sutilains	
tetanus toxoid	
tetracaine and its salts (for ophthalmic and parenteral use)	
tetrahydrozoline (in nasal preparations for pediatric use)	
thrombin	
thyroglobulin	
thyrotropin	
triamcinolone acetonide in an aqueous nasal spray that delivers 55mcg per metered spray for adults and children 12 years of age and older, in package sizes containing more than 120 metered sprays	
urea in topical preparations in concentrations greater than 25%	
vaccines, which are part of a routine immunization program in most/all provinces and territories	
vitamins (any parenterals not included in Schedule I)	
xylometazoline and its salts (in nasal preparations for pediatric use (0.05%))	
xylose	

SCHEDULE III – PHARMACY SALE ONLY

Schedule III drugs may present risks to certain populations in self-selection. Although available without a prescription, these drugs are to be sold from the self-selection area of the pharmacy which is operated under the direct supervision of the pharmacist. Such an environment is accessible to the patient and clearly identified as the “professional services area” of the pharmacy. The pharmacist is available, accessible and approachable to assist the patient in making an appropriate self-care selection.

The following table provides a current list of Schedule III drugs. **Recent changes are indicated with BOLD UNDERLINE**. Examples of the Brand Names of products containing these drugs are also provided. Please note that the list of Brand Names is not necessarily inclusive and are provided for reference only.

Chemical name as it appears in the Schedule	Examples of common Brand Names
acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen	
acetaminophen in sustained release formulations (in strengths of greater than 650 mg per unit or in package sizes of more than 50 units)	<ul style="list-style-type: none"> • Tylenol Arthritis Pain 8H (100's, 170's, 200's) • Tylenol Muscle & Body 8H (72's, 110's)
acetylsalicylic acid and its salts (in products intended for oral adult use in strengths of 81mg per dosage unit and 650mg or greater per dosage unit, and in rectal preparations containing more than 150 mg per dosage unit)	<ul style="list-style-type: none"> • Aspirin 81mg Daily Low Dose / 81mg Quick Chews • Entrophen 81mg Daily Low Dose / 81mg Chewable • Novasen 650m
amylocaine and its salts (in preparations for topical use on mucous membranes except lozenges)	
anethole trithione	
antazoline and its salts	<ul style="list-style-type: none"> • Refresh Eye Allergy Relief
antipyrine (for otic use)	<ul style="list-style-type: none"> • Auralgan
bacitracin and its salts and derivatives (for ophthalmic use)	
benzonatate	
bisacodyl and its salts (except when sold in concentrations of 5mg or less per oral dosage unit in package sizes containing no more than 105mg of bisacodyl or 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl)	
brompheniramine and its salts as a single entity for the treatment of allergies	
bupivacaine and its salts (for topical use on mucous membranes except lozenges)	
calcium polycarbophil	
carbinoxamine and its salts	
cepron	
cetirizine and its salts (in concentrations of 10 mg equivalent to 8.5 mg or less of cetirizine base per dosage unit) in products marketed for pediatric use (under 12 years of age)	<ul style="list-style-type: none"> • Reactine Children's Liquid / Fast Melt
chlorthalidone and its salts	
chloroprocaine and its salts (for topical use on mucous membranes except lozenges)	
chlorzoxazone and its salts	<ul style="list-style-type: none"> • Acetazone Forte
cimetidine and its salts (in concentrations of 100 mg or less per dosage unit)	
clemastine and its salts	
clotrimazole and its salts (in preparations for vaginal use)	<ul style="list-style-type: none"> • Canesten vaginal products • Clotrimaderm vaginal creams
danthron	
dehydrocholic acid and its salts	
desloratadine and its salts and preparations in products marketed for pediatric use (under 12 years of age)	<ul style="list-style-type: none"> • Aerius Kids Syrup

Chemical name as it appears in the Schedule	Examples of common Brand Names
dexbrompheniramine and its salts	
dexchlorpheniramine and its salts	
dextromethorphan and its salts	<ul style="list-style-type: none"> Balminil DM products / Night-Time Benlylin All in One Cold & Flu products / "Cough" products / DM products / Mucus & Phlegm Relief products / Tickly Throat Cough Buckley's Complete products / Daytime & Nighttime Cold and Sinus Coricidin Cold & Flu Extra Strength Dimetapp DM Cough & Cold Jack & Jill Cough & Cold Liquid NeoCitran Extra Strength Total Cold / Ultra Strength Total Flu Robitussin Complete / Cough & Cold / Cough Control / CoughGels / Total Cough, Cold & Flu Tylenol "Cough" products / Cold Daytime & Nighttime / Plus Mucus Relief / Flu Daytime & Nighttime Vicks Children's Nyquil Cold & Cough / Dayquil Cold & Flu / Dayquil "Cough" products / Nyquil Cold & Flu / Nyquil "Cough" products
diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days - in concentrations greater than 1.16% and less than or equal to 2.32% - in package sizes containing no more than 2.6g of diclofenac diethylamine	<ul style="list-style-type: none"> Voltaren Emulgel Extra Strength (in package sizes less than 112gm)
dimenhydrinate and its salts (for oral or rectal use) (Please Note: Pharmacists are advised that in areas here there is evidence of abuse or a particular concern about abuse, dimenhydrinate products should not be located in a self-selection area of the pharmacy. Please also see NLPB Guidance regarding the sale of dimenhydrinate ²)	<ul style="list-style-type: none"> Gravol products generic and store brands
dimethothiazine	
dimeticone 100 cSt solution 50% w/w for topical use in the treatment of head lice	<ul style="list-style-type: none"> NYDA
diphenhydramine and its salts and preparations for topical use in concentrations of 2% or less when sold in containers of greater than 300mg of diphenhydramine hydrochloride	<ul style="list-style-type: none"> Benadryl cream / spray Calamine lotion + antihistamines
diphenhydramine and its salts and preparations (except for parenteral use)	<ul style="list-style-type: none"> Advil Cold & Flu / Nighttime Aleve Nighttime Benadryl oral products Benlylin All in One Cold & Flu Night Buckley's Night Time Mixture Jack & Jill Bedtime Neo Citran Total Cold Night Nycol products except Nycol Natural Source Sinutab Sinus Nighttime Extra Strength Sleep-Eze products except V Natural Tylenol Children's Cold & Cough Nighttime / Complete Cold, Cough & Flu Nighttime Unisom products except Unisom-2 ZZZ-Quil
diphenylpyraline	
doxylamine and its salts (except those sold for nausea and vomiting of pregnancy)	<ul style="list-style-type: none"> Buckley's Complete Nighttime / Nighttime Cold & Sinus NyQuil Cold & Flu Nighttime / Complete Cold & Flu / Cough / Sinus Robitussin Complete Nighttime Tylenol Cold & Flu Nighttime
dyclonine and its salts (for topical use on mucous membranes except lozenges)	

² Available on the Drug Schedules page of the NLPB website: <https://nlpb.ca/pharmacy-practice/provincial-drug-schedules/>

Chemical name as it appears in the Schedule	Examples of common Brand Names
ephedrine and its salts in combination products (in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use for not more than 7 days, and indicated for nasal congestion) [Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, ephedrine products should NOT be located in a self-selection area of the pharmacy]	
esomeprazole or its salts, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole	<ul style="list-style-type: none"> Nexium 24HR
famotidine and its salts, when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 600 mg of famotidine	
fexofenadine hydrochloride (in products marketed for paediatric use (under 12 years of age))	
fluconazole when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole	<ul style="list-style-type: none"> CanesOral Diflucan One Monicure
fluticasone propionate, when sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing no more than 360 metered sprays	
fractar	
glyceroargentine	
gramicidin and its salts and derivatives (for ophthalmic use)	<ul style="list-style-type: none"> Optimyxin eye/ear drops Polysporin Eye and Ear drops
haloprogin	
ibuprofen and its salts, containing 400mg or less per oral dosage unit (when sold in package sizes exceeding 18,000mg)	<ul style="list-style-type: none"> Advil single-entity 200mg products (more than 90 tablets) Advil single-entity 400mg products (more than 45 tablets) Motrin single-entity 200mg products (more than 90 tablets) Motrin single-entity 300mg products (more than 60 tablets) Motrin single-entity 400mg products (more than 45 tablets)
ibuprofen or its salts, when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit	<ul style="list-style-type: none"> Advil 12 Hour
isopropyl myristate in concentration of 50% (for use in the treatment of head lice)	<ul style="list-style-type: none"> Resultz
lactulose	
levonorgestrel (when sold in concentrations of 0.75 mg per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel)	<ul style="list-style-type: none"> Plan B
lidocaine and its salts (for otic use)	<ul style="list-style-type: none"> Polysporin Plus Pain Relief ear drops
lidocaine and prilocaine (eutectic mixture)	<ul style="list-style-type: none"> EMLA cream and patches
loratadine and its salts and preparations in products marketed for pediatric use (under 12 years of age)	<ul style="list-style-type: none"> Claritin Kids Syrup
meclizine and its salts (when sold in concentrations of 25mg or less per dosage unit)	
mepivacaine and its salts (for topical use on mucous membranes except lozenges)	
methocarbamol (except for parenteral use)	<ul style="list-style-type: none"> Motrin Platinum Muscle and Body Robax Platinum / Robaxacet / Robaxin / Robaxin 750 / Robaxisal Tylenol Extra Strength Back Pain
miconazole and its salts (for vaginal use)	<ul style="list-style-type: none"> Monistat vaginal products
mineral tar (except shampoos with concentrations less than 5%)	

Chemical name as it appears in the Schedule	Examples of common Brand Names
naproxen and its salts, in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit (when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base.) [*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]	<ul style="list-style-type: none"> Aleve (100 tablets or more)
nystatin and its salts and derivatives (in topical preparations for use on the skin)	<ul style="list-style-type: none"> Nyaderm cream generic brands
orphenadrine citrate	
oxethazine	
oxybuprocaine and its salts (for topical use on mucous membranes except lozenges)	
phenyltoloxamine and its salts	
polymyxin B and its salts and derivatives (for ophthalmic use)	<ul style="list-style-type: none"> Optimyxin eye/ear drops Polysporin Eye and Ear drops
pramoxine and its salts (for topical use on mucous membranes except lozenges)	
prilocaine and its salts (for topical use on mucous membranes except lozenges)	
procaine and its salts (for topical use on mucous membranes except lozenges)	
promethazine and its salts (for topical use)	
proparacaine and its salts (for topical use on mucous membranes except lozenges)	
pseudoephedrine and its salts and preparations in combination products (Please Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, pseudoephedrine products should NOT be located in a self-selection area of the pharmacy)	<ul style="list-style-type: none"> Advil Cold & Sinus products / Children's Advil Cold / Cold & Flu Aerius Dual Action 12 Hour Allegra D Benadryl Total Benlyn All-in-One Cold & Flu / Cough & Chest Congestion / "D" products Buckley's Cough & Cold / Cough, Cold & Flu / Cold & Sinus Claritin Allergy + Sinus NeoCitran Flu with Mucous Relief / Flu Night Reactine Complete Robitussin Cough & Cold / Total Cough, Cold & Flu Sinutab Sinus / Sinus & Allergy Sudafed Head Cold & Sinus / Sinus / Sinus Advance Tylenol Cold & Sinus / Complete Cold, Cough & Flu Tylenol Children's Cold / Cold & Cough / Cold & Stuffy Nose / Complete Cold, Cough & Fever
ranitidine and its salts, when sold in concentrations of 150mg or less per oral dosage unit & indicated for the treatment of heartburn, in package sizes containing more than 4,500mg of ranitidine	
sodium biphosphate (cathartics)	
sodium cromoglycate (in solutions in concentrations of 2% or less for ophthalmic or nasal use)	<ul style="list-style-type: none"> Cromolyn eye drops Opticrom Rhinaris-CS Anti-Allergic Nasal Mist
sodium phosphate (cathartics)	
tetracaine and its salts (for topical use on mucous membranes except lozenges)	
tioconazole and its salts (in preparations for vaginal use)	
triethanolamine oleate	
triethanolamine salicylate (in concentrations greater than 20%)	
tripelennamine and its salts	
triprolidine	

Chemical name as it appears in the Schedule	Examples of common Brand Names
tyrothricine	
triamcinolone acetonide in an aqueous nasal spray that delivers 55mcg per metered spray for adults and children 12 years of age and older, in package sizes containing no more than 120 metered sprays	<ul style="list-style-type: none"> • Nasacort Allergy 24HR
vegetable tar (except shampoos in concentrations of 5% or less)	

UNSCHEDULED DRUG PRODUCTS

Many drugs have been reviewed by the National Drug Scheduling Advisory Committee (NDSAC) but have not been assigned any place in the above schedules. As well, many drugs that are included in the schedules are included based on specific parameters such as strength and dosage form. That same drug in another strength or dosage form may be considered "Unscheduled".

Unscheduled drugs can be sold without professional supervision. Adequate information is available for the patient to make a safe and effective choice and labelling is deemed sufficient to ensure the appropriate use of the drug. These drugs may be sold from any retail environment.

The following table lists all drugs that are currently specifically recommended for unscheduled status by NDSAC. It is not intended to reflect all drugs not otherwise captured by the Provincial Drug Schedules. **Recent changes are indicated with BOLD UNDERLINE**. Examples of the Brand Names of products containing these drugs are also provided. Please note that the list of Brand Names is not necessarily inclusive and are provided for reference only.

Chemical name	Examples of common Brand Names
acetaminophen (in immediate release tablets, capsules, suppositories or liquid)	<ul style="list-style-type: none"> • Atasol Forte • Tempra products • Tylenol products
acetaminophen in sustained release formulations (up to and including 650 mg per unit, in package sizes containing no more than 50 units)	<ul style="list-style-type: none"> • Tylenol Arthritis Pain 8H • Tylenol Muscle & Body 8H
acetylsalicylic acid and its salts (in products for oral use in strengths of 325mg and 500mg per dosage unit)	<ul style="list-style-type: none"> • Alka-Seltzer products • Anacin products • Aspirin Regular / Extra Strength • Novasen 325mg
bacitracin and its salts (for topical use)	<ul style="list-style-type: none"> • Bacitin ointment • Band Aid adhesive bandages plus antibiotic • Ozonol Antibiotics Plus • Polysporin Antibiotic ointment / Triple Antibiotic ointment / Complete
benzoyl peroxide (preparations of 5% or less as a single ingredient)	<ul style="list-style-type: none"> • Advantage Acne Control Kit • Benzagel products • Clean & Clear Persa-Gel 5 • Clearasil Daily Clear Acne Treatment Cream BP Plus • Continuous Control Acne Cleanser • Deep Pore Acne Vanishing Treatment • Emergency Acne Vanishing Facial Cleanser • Spectro AcneCare Wash
bisacodyl and its salts (when sold in concentrations of 5mg or less per oral dosage unit in package sizes containing no more than 105mg of bisacodyl or 10mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50mg of bisacodyl)	
brompheniramine and its salts in combination products for the relief of cough and cold symptoms	<ul style="list-style-type: none"> • Dimetapp liquid • Robitussin Children's Cold
butenafine (1% cream)	
cetirizine and its salts (in concentrations of 10 mg equivalent to 8.5 mg or less of cetirizine base per dosage unit) in products marketed for adult use (12 years of age and older)	<ul style="list-style-type: none"> • Reactine 10mg tablets (single-entity)
charcoal (activated) except for use in poisoning treatment	
chloral hydrate (for topical use)	
chlorpheniramine and its salts and preparations	<ul style="list-style-type: none"> • Benylin Cold & Sinus Night • Chlor-Tripolon • Tylenol Extra Strength Sinus Nighttime
cinnamedrine	

Chemical name	Examples of common Brand Names
clotrimazole and its salts (in preparations for topical use)	<ul style="list-style-type: none"> • Canestan 1% Topical Cream
coal tar (in concentrations up to and including 10%)	
desloratidine and its salts and preparations (in products marketed for adult use – 12 years and older)	<ul style="list-style-type: none"> • Aerius tablets
diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16% for not more than 7 days	<ul style="list-style-type: none"> • Voltaren Emulgel regular strength products
diphenhydramine and its salts and preparations for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydramine hydrochloride	<ul style="list-style-type: none"> • Benadryl Itch Relief Stick
docosanol 10% for topical use	<ul style="list-style-type: none"> • Abreva ointment
docusate and its salts	<ul style="list-style-type: none"> • Colace products • Senokot S • Soflax products
famotidine and its salts, when sold in concentrations of 20mg or less of famotidine per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 600mg of famotidine	<ul style="list-style-type: none"> • Pepcid AC 10mg (60 tablets or less) • Pepcid AC Maximum Strength 20mg (30 tablets or less)
fexofenadine HCl (in products marketed for adult use – 12 years and older)	<ul style="list-style-type: none"> • Allegra 12 hour / 24 hour
gramicidin and its salts (for topical use)	<ul style="list-style-type: none"> • Polysporin Cream / Complete / Plus Pain Relief / For Kids / Triple Antibiotic Ointment
guaifenesin	<ul style="list-style-type: none"> • Balminil Expectorant • Benylin “E” / Mucous & Phlegm • Robitussin Mucus & Phlegm
ibuprofen and its salts, containing 400mg or less per oral dosage unit (when sold in package sizes of up to 18,000mg)	<ul style="list-style-type: none"> • Advil single-entity 200mg products (90 tablets or less) • Advil single-entity 400mg products (45 tablets or less) • Motrin single-entity 200mg products (90 tablets or less) • Motrin single-entity 300mg products (60 tablets or less) • Motrin single-entity 400mg products (45 tablets or less)
ketoconazole and its salts (as a shampoo)	<ul style="list-style-type: none"> • Nizoral 2% shampoo
lidocaine and its salts (for topical use on the skin, including lozenges)	<ul style="list-style-type: none"> • After Sun Soothing Spray • Afterburn • Bactine First Aid Spray • Band-Aid Brand Antiseptic Wash • Ozonol Antibiotics Plus • Polysporin Complete / For Kids / Plus Pain Relief • Solarcaine First Aid Lidocaine Spray / Medicated First Aid Lotion / Medicated Lidocaine Gel
loperamide and its salts in products marketed for adult use – 12 years and older)	<ul style="list-style-type: none"> • Imodium products
loratadine and its salts and preparations in products marketed for adult use (12 years of age and older)	<ul style="list-style-type: none"> • Claritin adult products (single entity)
miconazole and its salts (for topical use)	<ul style="list-style-type: none"> • Micatin Cream / Spray • Monistat Derm Cream
minoxidil, when sold in preparations for topical use in adults in concentrations of 5% or less, for human use only	
naphazoline and its salts (in nasal preparations for adult use and in ophthalmic products)	<ul style="list-style-type: none"> • Albalon • Clear Eyes / Clear Eyes Allergy / Extra Strength Redness Relief • Naphcon A • Opti-Tears Allergy • Refresh Redness Relief • Soothe Allergy / Redness • Visine for Allergy with Antihistamine

Chemical name	Examples of common Brand Names
naproxen and its salts, in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit (when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less.) [*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]	<ul style="list-style-type: none"> • Aleve (24's)
oxiconazole (1% for topical use)	
oxymetazoline (in nasal preparations for adult use and in ophthalmic products)	<ul style="list-style-type: none"> • Claritin Allergy Decongestant nasal spray • Dristan Long Lasting nasal sprays • Drixoral nasal sprays
pheniramine	<ul style="list-style-type: none"> • Dristan Nasal Mist • Naphcon-A • NeoCitran Cold & Sinus Night / Cold & Sore Throat Night • Opti-Tears Allergy • Soothe Allergy • Visine for Allergy with Antihistamine
phenylephrine and its salts and preparations (for oral use, in nasal preparations for adults and in ophthalmic preparations in concentrations of 2.5% or less)	<ul style="list-style-type: none"> • Benlyn Cold & Sinus / Cold & Sinus Plus caplets • Dayquil Sinus • Dimetapp liquid • Dristan Tablets / Nasal Mist • NeoCitran Cold & Congestion / Cold & Sinus Night / Cold & Sore Throat Night • Robitussin's Children's Cold
polyethylene glycol (topical administration)	
polyethylene glycol 3350 as a single ingredient oral product indicated as a laxative to treat occasional constipation	<ul style="list-style-type: none"> • Clearlax • Lax-A-Day • Pegalax • Purelax • Restoralax
polymyxin and its salts and derivatives (topical)	<ul style="list-style-type: none"> • Band aid adhesive bandages plus antibiotic • Ozonol Antibiotics Plus • All Polysporin topical products
pramoxine and its salts for topical application on the skin and including lozenges	<ul style="list-style-type: none"> • Aveeno Anti-Itch Lotion • Gold Bond Anti-Itch Lotion / Medicated Anti-Itch cream • Polysporin Itch Relief / Poly-To-Go
propylene glycol (topical application)	
pyrilamine	<ul style="list-style-type: none"> • Menstrual Midol Complete / PMS Midol Complete
ranitidine and its salts, when sold in concentrations of 150mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4500mg of ranitidine	<ul style="list-style-type: none"> • Zantac 75 • Zantac 150
sodium tartrate	
tetrahydrozoline (for ophthalmic use and in nasal preparations for adults)	<ul style="list-style-type: none"> • Clear Eyes Triple Action Relief • Visine Allergy / Multi-Symptom / Original / Red Eye
tioconazole and its salts (in preparations for topical use)	
triethanolamine salicylate (in concentrations up to and including 20%) [trolamine]	<ul style="list-style-type: none"> • Aspercreme • Myoflex products
xylometazoline and its salts (in nasal preparations for adults(0.1%))	<ul style="list-style-type: none"> • Balminil Decongest spray • Otrivin Cold & Allergy products

**APPENDIX A
PROVINCIAL REGULATIONS**

DRUG SCHEDULES

13. (1) The board may adopt the drug schedules established under the National Association of Pharmacy Regulatory Authorities National Drug Schedules System.

(2) Notwithstanding subsection (1), a pharmacist in charge may, where he or she considers it necessary, exercise a higher degree of control over a particular drug than what is contemplated in the schedules.

APPENDIX B SCHEDULING CRITERIA

FACTORS FOR THE INCLUSION OF DRUGS IN SCHEDULE I

1. Indications for use of the drug are identifiable only by the practitioner. Diagnosis of the indication requires intervention by the practitioner before the drug is used.
2. Use of the drug requires adjunctive therapy or evaluation. Adjunctive therapy could include other drugs, non-pharmacologic measures, or specialized drug delivery devices. Evaluation could include indicated laboratory or clinical assessments.
3. Use of the drug may produce dependency. The drug may cause addiction or become habit forming. Control of access and duration of therapy by a health care professional is required.
4. Serious adverse reactions to the drug are known to occur or have a recognized potential to occur at normal therapeutic dosage levels. Adverse experiences require special monitoring or intervention by a health care professional.
5. There exists a narrow margin of safety between the therapeutic and toxic dosages of the drug, either in the general population, or in identified subpopulations, or in patients with multiple medical problems. Safe use requires the involvement and intervention of a health care professional.
6. Serious interactions of the drug are known to occur. Such interactions (drug-drug, drug-food, drug-disease) require special monitoring or intervention by a health care professional.
7. Use of the drug has contributed to, or is likely to contribute to, the development of resistant strains of microorganisms. Appropriate use, and/or the decision to continue treatment, requires evaluation by the practitioner.
8. The mechanism of action of the drug is known but the consequences of widespread use are not adequately established. Unexpected effects of the drug must be evaluated and reported by a health care professional.
9. The therapeutic effects of a newly released drug are based on new or unknown mechanisms of action, but the consequences of widespread use are not adequately established. Close monitoring of the patient is required by a health care professional for unanticipated effects.

FACTORS FOR THE INCLUSION OF DRUGS IN SCHEDULE II

1. The initial need for a drug is normally identified by the practitioner, in addition chronic, recurrent, or subsequent therapy must be monitored by the pharmacist. A prescription should not be required to obtain a drug if the patient can understand directions for continued use through the intervention of the pharmacist. Therefore, the patient should have access to the drug for subsequent treatment and use following the first diagnosis and prescription by the practitioner. This collaborative approach enhances patient care.
2. The drug must be readily available under exceptional circumstances when a prescription is not practical. Such a drug might be required for a serious medical situation and the patient should have access to it to prevent a possible health emergency. An example of such an exceptional circumstance is availability of injectable epinephrine for anaphylactic reactions.
3. The drug is intended for administration in a health care setting or under direction of a health care professional, or is in an injectable dosage form and is not otherwise included in Schedule I. Examples include preoperative or diagnostic agents and products used for immunization or desensitization.
4. Evidence of abuse of the drug has been reported, due to its inherent pharmacological action which has the potential for abuse. Monitoring by a health care professional is necessary.
5. The selection of the drug requires intervention by the pharmacist to confirm that an appropriate self-assessment has been made by the patient. Dosage form, for example, may be an important consideration.
6. Use of the drug may delay recognition or mask the symptoms of serious disease. Intervention by the pharmacist is necessary to ensure appropriate referral to the practitioner.
7. The drug may cause important adverse reactions, including allergies, or interacts with other drugs, foods, or disease states that cannot be adequately addressed through product labelling. Intervention by the pharmacist is necessary to assess patient risk to prevent such problems for an individual patient through interpretation and clarification of labelling.
8. Use of the drug requires reinforcement or an expansion of the directions for use, through pharmacist - patient dialogue. Such reinforcement and expansion may include the explanation of the use of a drug delivery system.

9. The drug is a new ingredient for self-medication and monitoring by the pharmacist is necessary to facilitate observation and reporting of any unexpected event.
10. The maximum labelled dosage directions exceed the generally accepted or usual limits for Schedule III status.

FACTORS FOR THE INCLUSION OF DRUGS IN SCHEDULE III

1. The initial need for a drug is normally identified by the patient, physician, or pharmacist, but chronic, recurrent, or subsequent therapy can be monitored by the pharmacist.
2. The maximum recommended duration of use of the drug is limited and specified on the product label. The pharmacist is available to explain that the consequences of not following the period of use may be serious and that persistence of symptoms may suggest an underlying ailment.
3. The maximum recommended duration of use of the drug is not specified on the label, but continued use may delay recognition or mask the symptoms of serious disease. The pharmacist is available to help in interpretation of symptoms, to assist in selection of alternative therapy, or to provide appropriate referral.
4. The drug is used to treat a persistent, chronic or recurring condition and the availability of the pharmacist to provide advice can promote appropriate use. The pharmacist should be available to direct the patient to a practitioner for assessment if the treatment period has been inappropriate or the therapy has been ineffective.
5. The drug is used for self-treatment of self-limiting ailments; however, where product selection has been identified as likely to cause patient confusion and the availability of the pharmacist to provide advice can promote appropriate use. Many product selections may be confusing for the patient. These choices are further complicated by the different forms of available therapy or dosage forms.
6. The drug demonstrates adverse effects, including allergies, or interacts with other drugs, foods, or disease states that can be identified in product labelling, but appropriate product selection and explanation of risk may require the advice of the pharmacist. For example, individuals taking a traditional monoamine oxidase inhibitor are aware that certain drugs should be avoided (e.g., cold products) but might require assistance in selecting a safe product to use.
7. The drug is a new ingredient for self-selected self-medication and the availability of the pharmacist to provide advice can promote appropriate use. The pharmacist is available to answer questions about this new ingredient.
8. The drug has inherent pharmacologic action which has the potential for non-medical use which may result in adverse patient outcomes.
9. The maximum labelled dosage directions exceed the generally accepted or usual limits for unscheduled status.

APPENDIX C
VACCINES AND IMMUNE GLOBULINS QUICK REFERENCE

SCHEDULE I	SCHEDULE II
<ul style="list-style-type: none"> ➤ Bacillus Calmette-Guerin ➤ Cholera (when <u>not</u> used for prophylaxis against Traveler's Diarrhea due to enterotoxigenic escherichia coli [ETEC]) ➤ Hepatitis A ➤ Hepatitis B Adult ➤ Herpes Zoster (shingles) ➤ Japanese Encephalitis ➤ Rabies ➤ Typhoid ➤ Varicella (chicken pox) ➤ Yellow Fever ➤ All Immune Globulins 	<ul style="list-style-type: none"> ➤ Cholera (oral, inactivated) (when used for prophylaxis against Traveler's Diarrhea due to enterotoxigenic escherichia coli [ETEC]) ➤ Diphtheria toxoid ➤ Haemophilus influenzae Type B ➤ Hepatitis B Pediatric ➤ Human Papillomavirus ➤ Influenza ➤ Measles ➤ Meningococcus ➤ Mumps ➤ Pertussis ➤ Pneumococcal conjugate (7-valent) ➤ Pneumococcal conjugate (13-valent) ➤ Pneumococcal polysaccharide ➤ Poliomyelitis ➤ Rotavirus ➤ Rubella ➤ Tetanus toxoid